Identification of de Novo Fanconi Anemia in Younger Patients With Newly Diagnosed Acute Myeloid Leukemia
Status: | Recruiting |
---|---|
Conditions: | Blood Cancer, Blood Cancer, Blood Cancer, Blood Cancer, Anemia, Anemia, Hematology |
Therapuetic Areas: | Hematology, Oncology |
Healthy: | No |
Age Range: | Any - 21 |
Updated: | 4/21/2016 |
Start Date: | October 2009 |
Identification of de Novo Fanconi Anemia Patients Using FANCD2 Western Blots
This research study is studying identification of de novo Fanconi anemia in younger patients
with newly diagnosed acute myeloid leukemia. Studying samples of tissue from patients with
cancer in the laboratory may help doctors identify and learn more about biomarkers related
to Fanconi anemia in patients with acute myeloid leukemia.
with newly diagnosed acute myeloid leukemia. Studying samples of tissue from patients with
cancer in the laboratory may help doctors identify and learn more about biomarkers related
to Fanconi anemia in patients with acute myeloid leukemia.
PRIMARY OBJECTIVES:
I. Identify children with newly diagnosed acute myeloid leukemia (AML) treated on COG-2961
and COG-AAML03P1 who are at high risk of having de novo Fanconi anemia.
II. Procure diagnostic samples from the COG AML Biology Repository and identify Fanconi
anemia patients using western blot techniques.
OUTLINE:
Previously collected cryopreserved cells are analyzed via western blot to identify patients
with Fanconi anemia.
I. Identify children with newly diagnosed acute myeloid leukemia (AML) treated on COG-2961
and COG-AAML03P1 who are at high risk of having de novo Fanconi anemia.
II. Procure diagnostic samples from the COG AML Biology Repository and identify Fanconi
anemia patients using western blot techniques.
OUTLINE:
Previously collected cryopreserved cells are analyzed via western blot to identify patients
with Fanconi anemia.
Inclusion Criteria:
- Treated on COG-2961 or COG-AAML03P1
- At high risk of having Fanconi anemia, defined as meeting one the following groups of
clinical criteria:
- Group 1: Prolonged neutropenia after induction, severe regimen-related toxicity
(mucositis, veno-occlusive disease, end-organ damage)
- Group 2: Early non-relapse death (induction, consolidation)
- Group 3: Small-for-weight, secondary malignancies
We found this trial at
1
site
Monrovia, California 91016
Principal Investigator: Monica S. Thakar, MD
Phone: 206-667-5946
Click here to add this to my saved trials